Malignant Pancreatic Neoplasm — Trials

Malignant Pancreatic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 904
Recruiting: 503
Ph III recruiting: 44
Growth YoY: +20.1%
Industry share: 32%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.5%
Trials / 1,000 deaths: 18.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (516)

clinicaltrialsPublishedShowing 651–700 of 1,346 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00625586	Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer	terminated	Phase 2	2	MacroGenicsINDUSTRY	1	Nov 3, 2023	clinicaltrials
NCT05988372	Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)	not yet recruiting	Phase 2	50	Sun Yat-sen UniversityOTHER	1	Nov 1, 2023	clinicaltrials